Globally, Glaucoma is the second leading cause of blindness after cataract. In India, approximately 11 million people have lost their vision due to this incurable disease. Compliance is a major concern in treating Glaucoma as nearly 50% of patients admit non-continuous use of medications by 6 months after start of therapy. Multiple dosing limits patient’s adherence to the treatment and thereby, worsens the condition. Patients feel that the treatment of Glaucoma is inconvenient and interferes with their day-to-day life. Bausch+Lomb’s Travoflo is a convenient once-daily-dosing therapy for Glaucoma, which is aimed at improving patient compliance by reducing the number of interruptions and improving the overall outcome.
Agency of the Year X Country Winners Showcase Creativity Defined by CultureRead More
McCann New York Wins 2017 Super Clio for a “Genius” National Geographic SpotRead More
How Agency of the Year X Country Winners Find Inspiration In Global and Tech TrendsRead More
How Havas CCO Jason Peterson Became the Advertising King of InstagramRead More